AnaptysBio was founded in 2005 by Brad Marsilio and Bobby Waugh. In 2012, the company received a Series A financing of $10 million. In 2015, they made their IPO, raising over $52 million. In 2017, they completed a phase 2a trial for the ANB020 drug and began the phase 2b trial.
